MedicarePartD.guide

A non-government resource built from CMS public data

JAK inhibitors and other oral immunology drugs on AARP Medicare Rx Saver from UHC (S5921-373)

Rinvoq, Xeljanz, Olumiant and Otezla, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), Nevada
Premium
$76.70/month
Deductible
$615.00
Change plan

1 of 5 JAK inhibitors is covered on this plan. It requires prior authorization.

4 aren't on the formulary, including Rinvoq and Xeljanz.

  • Otezla
    apremilast
    Covered · prior auth
    from $233.75
    Tier 5
Not on the formulary
Rinvoq, Xeljanz, Olumiant, Sotyktu

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list